5mgs - Revision history

OCA at 07:48, 7 February 2024

2024-02-07T07:48:21Z

←Older revision		Revision as of 07:48, 7 February 2024
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5mgs]] is a 8 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5MGS OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5MGS FirstGlance]. <br>		<table><tr><td colspan='2'>[[5mgs]] is a 8 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5MGS OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5MGS FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.9Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5mgs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5mgs OCA], [https://pdbe.org/5mgs PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5mgs RCSB], [https://www.ebi.ac.uk/pdbsum/5mgs PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5mgs ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5mgs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5mgs OCA], [https://pdbe.org/5mgs PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5mgs RCSB], [https://www.ebi.ac.uk/pdbsum/5mgs PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5mgs ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
	[https://www.uniprot.org/uniprot/KLRB1_HUMAN KLRB1_HUMAN] Plays an inhibitory role on natural killer (NK) cells cytotoxicity. Activation results in specific acid sphingomyelinase/SMPD1 stimulation with subsequent marked elevation of intracellular ceramide. Activation also leads to AKT1/PKB and RPS6KA1/RSK1 kinases stimulation as well as markedly enhanced T-cell proliferation induced by anti-CD3. Acts as a lectin that binds to the terminal carbohydrate Gal-alpha(1,3)Gal epitope as well as to the N-acetyllactosamine epitope. Binds also to CLEC2D/LLT1 as a ligand and inhibits NK cell-mediated cytotoxicity as well as interferon-gamma secretion in target cells.<ref>PMID:16455998</ref> <ref>PMID:16925668</ref> <ref>PMID:8077657</ref>		[https://www.uniprot.org/uniprot/KLRB1_HUMAN KLRB1_HUMAN] Plays an inhibitory role on natural killer (NK) cells cytotoxicity. Activation results in specific acid sphingomyelinase/SMPD1 stimulation with subsequent marked elevation of intracellular ceramide. Activation also leads to AKT1/PKB and RPS6KA1/RSK1 kinases stimulation as well as markedly enhanced T-cell proliferation induced by anti-CD3. Acts as a lectin that binds to the terminal carbohydrate Gal-alpha(1,3)Gal epitope as well as to the N-acetyllactosamine epitope. Binds also to CLEC2D/LLT1 as a ligand and inhibits NK cell-mediated cytotoxicity as well as interferon-gamma secretion in target cells.<ref>PMID:16455998</ref> <ref>PMID:16925668</ref> <ref>PMID:8077657</ref>
-	<div style="background-color:#fffaf0;">
-	== Publication Abstract from PubMed ==
-	Signaling by the human C-type lectin-like receptor, natural killer (NK) cell inhibitory receptor NKR-P1, has a critical role in many immune-related diseases and cancer. C-type lectin-like receptors have weak affinities to their ligands; therefore, setting up a comprehensive model of NKR-P1-LLT1 interactions that considers the natural state of the receptor on the cell surface is necessary to understand its functions. Here we report the crystal structures of the NKR-P1 and NKR-P1:LLT1 complexes, which provides evidence that NKR-P1 forms homodimers in an unexpected arrangement to enable LLT1 binding in two modes, bridging two LLT1 molecules. These interaction clusters are suggestive of an inhibitory immune synapse. By observing the formation of these clusters in solution using SEC-SAXS analysis, by dSTORM super-resolution microscopy on the cell surface, and by following their role in receptor signaling with freshly isolated NK cells, we show that only the ligation of both LLT1 binding interfaces leads to effective NKR-P1 inhibitory signaling. In summary, our findings collectively support a model of NKR-P1:LLT1 clustering, which allows the interacting proteins to overcome weak ligand-receptor affinity and to trigger signal transduction upon cellular contact in the immune synapse.
-
-	Structure of the human NK cell NKR-P1:LLT1 receptor:ligand complex reveals clustering in the immune synapse.,Blaha J, Skalova T, Kalouskova B, Skorepa O, Cmunt D, Grobarova V, Pazicky S, Polachova E, Abreu C, Stransky J, Koval T, Duskova J, Zhao Y, Harlos K, Hasek J, Dohnalek J, Vanek O Nat Commun. 2022 Aug 26;13(1):5022. doi: 10.1038/s41467-022-32577-6. PMID:36028489<ref>PMID:36028489</ref>
-
-	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	</div>
-	<div class="pdbe-citations 5mgs" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 07:40, 8 March 2023

2023-03-08T07:40:03Z

←Older revision		Revision as of 07:40, 8 March 2023
Line 3:		Line 3:
	<StructureSection load='5mgs' size='340' side='right'caption='[[5mgs]], [[Resolution\|resolution]] 1.90Å' scene=''>		<StructureSection load='5mgs' size='340' side='right'caption='[[5mgs]], [[Resolution\|resolution]] 1.90Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5mgs]] is a 8 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5MGS OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://proteopedia.org/fgij/fg.htm?mol=5MGS FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5mgs]] is a 8 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5MGS OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5MGS FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">KLRB1, CLEC5B, NKRP1A ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5mgs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5mgs OCA], [https://pdbe.org/5mgs PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5mgs RCSB], [https://www.ebi.ac.uk/pdbsum/5mgs PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5mgs ProSAT]</span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://proteopedia.org/fgij/fg.htm?mol=5mgs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5mgs OCA], [~~http~~://pdbe.org/5mgs PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5mgs RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5mgs PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5mgs ProSAT]</span></td></tr>	+
	</table>		</table>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/KLRB1_HUMAN KLRB1_HUMAN]] Plays an inhibitory role on natural killer (NK) cells cytotoxicity. Activation results in specific acid sphingomyelinase/SMPD1 stimulation with subsequent marked elevation of intracellular ceramide. Activation also leads to AKT1/PKB and RPS6KA1/RSK1 kinases stimulation as well as markedly enhanced T-cell proliferation induced by anti-CD3. Acts as a lectin that binds to the terminal carbohydrate Gal-alpha(1,3)Gal epitope as well as to the N-acetyllactosamine epitope. Binds also to CLEC2D/LLT1 as a ligand and inhibits NK cell-mediated cytotoxicity as well as interferon-gamma secretion in target cells.<ref>PMID:16455998</ref> <ref>PMID:16925668</ref> <ref>PMID:8077657</ref>	+	[https://www.uniprot.org/uniprot/KLRB1_HUMAN KLRB1_HUMAN] Plays an inhibitory role on natural killer (NK) cells cytotoxicity. Activation results in specific acid sphingomyelinase/SMPD1 stimulation with subsequent marked elevation of intracellular ceramide. Activation also leads to AKT1/PKB and RPS6KA1/RSK1 kinases stimulation as well as markedly enhanced T-cell proliferation induced by anti-CD3. Acts as a lectin that binds to the terminal carbohydrate Gal-alpha(1,3)Gal epitope as well as to the N-acetyllactosamine epitope. Binds also to CLEC2D/LLT1 as a ligand and inhibits NK cell-mediated cytotoxicity as well as interferon-gamma secretion in target cells.<ref>PMID:16455998</ref> <ref>PMID:16925668</ref> <ref>PMID:8077657</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Signaling by the human C-type lectin-like receptor, natural killer (NK) cell inhibitory receptor NKR-P1, has a critical role in many immune-related diseases and cancer. C-type lectin-like receptors have weak affinities to their ligands; therefore, setting up a comprehensive model of NKR-P1-LLT1 interactions that considers the natural state of the receptor on the cell surface is necessary to understand its functions. Here we report the crystal structures of the NKR-P1 and NKR-P1:LLT1 complexes, which provides evidence that NKR-P1 forms homodimers in an unexpected arrangement to enable LLT1 binding in two modes, bridging two LLT1 molecules. These interaction clusters are suggestive of an inhibitory immune synapse. By observing the formation of these clusters in solution using SEC-SAXS analysis, by dSTORM super-resolution microscopy on the cell surface, and by following their role in receptor signaling with freshly isolated NK cells, we show that only the ligation of both LLT1 binding interfaces leads to effective NKR-P1 inhibitory signaling. In summary, our findings collectively support a model of NKR-P1:LLT1 clustering, which allows the interacting proteins to overcome weak ligand-receptor affinity and to trigger signal transduction upon cellular contact in the immune synapse.
		+
		+	Structure of the human NK cell NKR-P1:LLT1 receptor:ligand complex reveals clustering in the immune synapse.,Blaha J, Skalova T, Kalouskova B, Skorepa O, Cmunt D, Grobarova V, Pazicky S, Polachova E, Abreu C, Stransky J, Koval T, Duskova J, Zhao Y, Harlos K, Hasek J, Dohnalek J, Vanek O Nat Commun. 2022 Aug 26;13(1):5022. doi: 10.1038/s41467-022-32577-6. PMID:36028489<ref>PMID:36028489</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 5mgs" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Blaha, J]]	+	[[Category: Blaha J]]
-	[[Category: Dohnalek, J]]	+	[[Category: Dohnalek J]]
-	[[Category: Harlos, K]]	+	[[Category: Harlos K]]
-	[[Category: Hasek, J]]	+	[[Category: Hasek J]]
-	[[Category: Koval, T]]	+	[[Category: Koval T]]
-	[[Category: Skalova, T]]	+	[[Category: Skalova T]]
-	[[Category: Stransky, J]]	+	[[Category: Stransky J]]
-	[[Category: Vanek, O]]	+	[[Category: Vanek O]]
-	[[Category: Yuguang, Z]]	+	[[Category: Yuguang Z]]
-	~~[[Category: Ctl fold]]~~	+
-	~~[[Category: Immune system]]~~	+
-	~~[[Category: Natural killer cell]]~~	+
-	~~[[Category: Receptor~~]]	+

OCA at 07:19, 19 August 2020

2020-08-19T07:19:08Z

←Older revision		Revision as of 07:19, 19 August 2020
Line 1:		Line 1:

	==Human receptor NKR-P1 in deglycosylated form, extracellular domain==		==Human receptor NKR-P1 in deglycosylated form, extracellular domain==
-	<StructureSection load='5mgs' size='340' side='right' caption='[[5mgs]], [[Resolution\|resolution]] 1.90Å' scene=''>	+	<StructureSection load='5mgs' size='340' side='right'caption='[[5mgs]], [[Resolution\|resolution]] 1.90Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5mgs]] is a 8 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5MGS OCA]. For a <b>guided tour on the structure components</b> use [http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5MGS FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5mgs]] is a 8 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5MGS OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5MGS FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5mgs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5mgs OCA], [http://pdbe.org/5mgs PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5mgs RCSB], [http://www.ebi.ac.uk/pdbsum/5mgs PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5mgs ProSAT]</span></td></tr>	+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">KLRB1, CLEC5B, NKRP1A ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5mgs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5mgs OCA], [http://pdbe.org/5mgs PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5mgs RCSB], [http://www.ebi.ac.uk/pdbsum/5mgs PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5mgs ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
Line 13:		Line 14:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Blaha, J]]		[[Category: Blaha, J]]
	[[Category: Dohnalek, J]]		[[Category: Dohnalek, J]]

OCA at 07:11, 23 May 2018

2018-05-23T07:11:52Z

←Older revision		Revision as of 07:11, 23 May 2018
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 5mgs is ~~ON HOLD~~ ~~until Paper Publication~~	+	==Human receptor NKR-P1 in deglycosylated form, extracellular domain==
-		+	<StructureSection load='5mgs' size='340' side='right' caption='[[5mgs]], [[Resolution\|resolution]] 1.90Å' scene=''>
-	~~Authors~~:	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[5mgs]] is a 8 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5MGS OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5MGS FirstGlance]. <br>
-	~~Description~~:	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
-	[[Category: ~~Unreleased Structures~~]]	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5mgs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5mgs OCA], [http://pdbe.org/5mgs PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5mgs RCSB], [http://www.ebi.ac.uk/pdbsum/5mgs PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5mgs ProSAT]</span></td></tr>
		+	</table>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/KLRB1_HUMAN KLRB1_HUMAN]] Plays an inhibitory role on natural killer (NK) cells cytotoxicity. Activation results in specific acid sphingomyelinase/SMPD1 stimulation with subsequent marked elevation of intracellular ceramide. Activation also leads to AKT1/PKB and RPS6KA1/RSK1 kinases stimulation as well as markedly enhanced T-cell proliferation induced by anti-CD3. Acts as a lectin that binds to the terminal carbohydrate Gal-alpha(1,3)Gal epitope as well as to the N-acetyllactosamine epitope. Binds also to CLEC2D/LLT1 as a ligand and inhibits NK cell-mediated cytotoxicity as well as interferon-gamma secretion in target cells.<ref>PMID:16455998</ref> <ref>PMID:16925668</ref> <ref>PMID:8077657</ref>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Blaha, J]]
		+	[[Category: Dohnalek, J]]
		+	[[Category: Harlos, K]]
		+	[[Category: Hasek, J]]
		+	[[Category: Koval, T]]
		+	[[Category: Skalova, T]]
		+	[[Category: Stransky, J]]
		+	[[Category: Vanek, O]]
		+	[[Category: Yuguang, Z]]
		+	[[Category: Ctl fold]]
		+	[[Category: Immune system]]
		+	[[Category: Natural killer cell]]
		+	[[Category: Receptor]]

OCA at 16:16, 15 December 2016

2016-12-15T16:16:39Z

←Older revision		Revision as of 16:16, 15 December 2016
Line 3:		Line 3:
	The entry 5mgs is ON HOLD until Paper Publication		The entry 5mgs is ON HOLD until Paper Publication

-	Authors: ~~Skalova, T., Blaha, J., Stransky, J., Koval, T., Hasek, J., Yuguang, Z., Harlos, K., Vanek, O., Dohnalek, J.~~	+	Authors:

-	Description: ~~Human receptor NKR-P1 in deglycosylated form, extracellular domain~~	+	Description:
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
-	[[Category: Dohnalek, J]]
-	[[Category: Hasek, J]]
-	[[Category: Koval, T]]
-	[[Category: Yuguang, Z]]
-	[[Category: Skalova, T]]
-	[[Category: Harlos, K]]
-	[[Category: Stransky, J]]
-	[[Category: Blaha, J]]
-	[[Category: Vanek, O]]

OCA: Protected "5mgs" [edit=sysop:move=sysop]

2016-12-09T16:50:21Z

Protected "5mgs" [edit=sysop:move=sysop]

←Older revision

Revision as of 16:50, 9 December 2016

OCA: New page: '''Unreleased structure''' The entry 5mgs is ON HOLD until Paper Publication Authors: Skalova, T., Blaha, J., Stransky, J., Koval, T., Hasek, J., Yuguang, Z., Harlos, K., Vanek, O., Doh...

2016-12-09T16:50:20Z

New page: '''Unreleased structure''' The entry 5mgs is ON HOLD until Paper Publication Authors: Skalova, T., Blaha, J., Stransky, J., Koval, T., Hasek, J., Yuguang, Z., Harlos, K., Vanek, O., Doh...

New page

'''Unreleased structure'''

The entry 5mgs is ON HOLD until Paper Publication

Authors: Skalova, T., Blaha, J., Stransky, J., Koval, T., Hasek, J., Yuguang, Z., Harlos, K., Vanek, O., Dohnalek, J.

Description: Human receptor NKR-P1 in deglycosylated form, extracellular domain
[[Category: Unreleased Structures]]
[[Category: Dohnalek, J]]
[[Category: Hasek, J]]
[[Category: Koval, T]]
[[Category: Yuguang, Z]]
[[Category: Skalova, T]]
[[Category: Harlos, K]]
[[Category: Stransky, J]]
[[Category: Blaha, J]]
[[Category: Vanek, O]]